Evidence — SS-31
peptide · asset evidence level: clinical
Evidence quality breakdown (linked documents)
expert_opinion: 4preclinical: 1
Linked source documents (5)
- Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import) (physician_protocol · expert_opinion)
- Copy of Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (physician_protocol · expert_opinion)
- Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (physician_protocol · expert_opinion)
- Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (physician_protocol · expert_opinion)
- SS-31: Mechanistic Overview (internal_protocol · preclinical)
Provider dosing references (Stage 9, source-attributed)
Investigational; commonly studied at 40 mg SC daily - provider-directed — Practitioner Peptide Dosing Reference (commonly published ranges)
Dosing claims (1) · Safety claims (1)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.